Analyst consensus rating

Lakewood-Amedex Biotherapeutics Analyst Rating: none

Direct answer

Lakewood-Amedex Biotherapeutics's consensus rating is none.

2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.50.
Forecast evidence checked November 16, 2026.

Get free Lakewood-Amedex Biotherapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$0.28
Average price target
$7.50
High price target
$12.00
Low price target
$3.00
Low target gap
+962.3%
Target upside
+2,555.8%
High target gap
+4,149.3%
Target range width
3,187%
Consensus rating
none
Analysts
2
Evidence date
November 16, 2026
Valid through
November 23, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Lakewood-Amedex Biotherapeutics?

Lakewood-Amedex Biotherapeutics has a verified none consensus. The same dataset has an average price target of $7.50.

How far are Lakewood-Amedex Biotherapeutics's low and high targets from the recorded price?

The low target implies +962.3%, while the high target implies +4,149.3%.

How many analysts are included in Lakewood-Amedex Biotherapeutics's consensus?

The verified consensus includes 2 analysts.

How is Lakewood-Amedex Biotherapeutics's target upside or downside calculated?

The average target of $7.50 is divided by the recorded price of $0.28, then one is subtracted to produce +2,555.8%. This does not guarantee a future return.

When was Lakewood-Amedex Biotherapeutics's analyst forecast verified?

The data was verified on 2026-11-16. The dataset is valid through 2026-11-23.